News Image

Daxor Unveils New FDA-Cleared BVA Analyzer Amid Strong Market Demand and Pivotal Clinical Data at HFSA

Provided By GlobeNewswire

Last update: Sep 30, 2025

Three Studies Validate BVA-Guided Care Significantly Cuts Hospital Readmissions and Boosts Survival in High-Cost Heart Failure Segments

OAK RIDGE, TN, Sept. 30, 2025 (GLOBE NEWSWIRE) -- Daxor Corporation (Nasdaq: DXR), the global leader in blood volume measurement technology, today announces significant commercial momentum and clinical validation following the Heart Failure Society of America (HFSA) Annual Scientific Meeting. The company’s successful debut of its newly FDA-cleared, next-generation BVA analyzer signals a new era of data-driven fluid management for a multi-billion-dollar market.

Read more at globenewswire.com

DAXOR CORP

NASDAQ:DXR (10/17/2025, 8:07:29 PM)

12.9456

-0.05 (-0.42%)



Find more stocks in the Stock Screener

Follow ChartMill for more